UNC Lineberger’s Matthew Milowsky, MD, the George Gabriel Villere Distinguished Professor of Bladder and Genitourinary Cancer Research, section chief of Genitourinary Oncology and co-director of the Urologic Oncology Program, was published in JAMA Oncology. He was a co-author on the paper, which was published as a special communication in the journal.
The report details discussions held during a workshop convened in November 2017 by the U.S. Food and Drug Administration and the National Cancer Institute, with support from the Society of Urologic Oncology, at the National Institutes of Health. The national experts in bladder cancer clinical trial research at the workshop discussed protocol criteria for adjuvant clinical trials of muscle-invasive bladder cancer and kidney cancer.
The effort focused on four topics related to muscle-invasive bladder cancer adjuvant trials: the role of patient and disease characteristics, defining radiographic eligibility, defining disease recurrence, and management of non–muscle-invasive bladder cancer.